Calviri provides cancer treatment products by combining a unique, highly immunogenic source of neoantigens with a peptide array platform. Founded by Stephen Johnston in 2018, Calviri is backed by investors that include Mitzi Krockover and Jacque J. Sokolov and is headquartered in Tempe.